iRhythm Plunges on Q3 Miss and Mobile Cardiac Telemetry Delay
iRhythm Holdings missed Q3 estimates and delayed its Zio MCT product launch, sending shares sharply lower; raised guidance signals management confidence in the core business but the 58.1x forward P/E
iRhythm Plunges on Q3 Miss and Mobile Cardiac Telemetry Delay
NEW YORK, November 9 —
iRhythm Holdings, Inc. (IRTC) missed Q3 estimates and delayed its Zio MCT launch, stripping the catalyst the market had priced in at 58.1x forward earnings.
- Q3 results missed analyst expectations; trailing EPS at $-1.17 on $854mn TTM revenue growing 14.9% YoY
- At $90.22 and 58.1x forward P/E, the valuation has no room for execution misses; $82mn in trailing FCF is the fundamental floor
- Revised Zio MCT launch date and Q4 guidance reaffirmation are the next tests
Raising Guidance on the Same Call as a Product Delay Is the Tell
The wire story leads with the miss. The underweighted signal is that management raised guidance in the same breath. iRhythm Holdings (IRTC) is growing TTM revenue at 14.9% YoY on an $854mn base. That is not a company in structural trouble. What the guidance raise signals is management's confidence that Zio AT can carry the near-term load alone. What the gap-down visible in the chart signals is that investors are not granting that credit yet. Those two reads cannot both be right, and the Q4 call will force a resolution.
58.1x Forward P/E Assumes Two Products. Now There Is One.
The structural problem is clean. iRhythm trades at that forward P/E with trailing EPS of $-1.17. That multiple prices in a growth story with two engines: the established Zio AT patch and the upcoming Zio MCT platform. The delay removes one engine for at least one quarter, and Needham cut its price target specifically citing Zio AT weakness, meaning even the remaining engine faces scrutiny. A single-platform quarter at 58x is not a comfortable setup. The multiple was pricing execution on both; it is now getting execution on one.
$82mn in Free Cash Flow Proves the Core Business Has Real Economics
Not everything here is broken. iRhythm generated $82mn in trailing free cash flow on $854mn in revenue, a 9.6% FCF margin. That is not exceptional, but it is genuine, and it confirms Zio AT is not burning cash to grow. The FCF is the bull's backstop in a scenario where MCT keeps slipping. If you want to stress-test the valuation at different discount rates and growth assumptions, the DCF calculator handles the scenario arithmetic in under a minute. The honest bull case exists. It just requires MCT to eventually ship.
A Second MCT Slip Would Reprice This as a Broken Growth Story
Both Needham and BTIG lowered their price targets following the Q3 release, with BTIG maintaining its Buy rating despite the cut. When two firms trim targets on the same event and both name product execution as the driver, that convergence is a signal worth taking seriously. The specific number that would prove the bull case wrong: a second Zio MCT delay announced on the Q4 earnings call. If management delivers a credible, concrete revised timeline instead, the same multiple becomes arguable again. If MCT slips again, this becomes a growth stock without its growth engine, and those reprice differently than a temporary setback.
For a full look at IRTC fundamentals, generate an investor report at Basis Report's IRTC stock page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
iRhythm missed Q3 estimates and delayed its Zio MCT product, triggering a stock plunge and a price target cut from Needham.